CoChat
Sign Up
Cited by 13Antifungal resistance and susceptibilityYeasts and Rust Fungi StudiesFungal Infections and Studies

Impact of Candida auris on critically ill patients: a three-year observational study in a Greek intensive care unit

Open access
Katsiari, Maria, Nikolaou, Charikleia, Palla, Eleftheria, Theodoridou, Kalliopi, Tsakris, Athanasios, Vrioni, Georgia·2025·Pathogens
DOI 10.3390/pathogens14040328PMC PMC12030536
Open this paper in CoChat — free account

Abstract

Candida auris has emerged as a multidrug-resistant yeast implicated in healthcare-associated invasive infections and hospital outbreaks. The aim of the current 38-month period observational study in a multidisciplinary Intensive Care Unit (ICU) was to analyze the epidemiology, potential risk factors, management strategies, and patient outcomes of patients with C. auris. During the study period, 32 patients were identified with C. auris infection (6 patients) or colonization (26 patients) and their clinical characteristics and treatment-related factors were compared. Identification of C. auris isolates was confirmed by MALDI-TOF spectrometry. According to our results, regarding patient-related factors, no significant differences were identified. Regarding treatment-related factors, the proportion of patients already receiving corticosteroids (34.6% vs. 83.3%, p = 0.064) or being on renal replacement treatment (7.7% vs. 33.3%) was higher in infected patients. Median time elapsed from ICU admission to first positive culture was 7 (1–21) days and half of cases were ICU-imported. All strains were resistant to fluconazole and susceptible to echinocandines and amphotericin B. Crude mortality of the study population was 43.75%, similar to other previously reported candidemias. Rapid identification of C. auris, continued surveillance, and infection control practices are important elements for controlling successfully its spread in the hospital setting and for establishing promptly its transition from commensalism to infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pathogens14040328

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immunosuppressive medications, especially corticosteroids, have been reported to be a predisposing factor for C. auris colonization.

    “Immunosuppressive medications, especially corticosteroids, have been reported to be a predisposing factor for C. auris colonization.”

    From Host–Candida auris interactions in the skin (2026) · cites this paper as [54]

    The Discussion (page not available) lists corticosteroid use among potential risk factors in the case series, but frames the investigation around C. auris infection, not acquisition of colonization. The Results (§3.1, page not available) compare infected with colonized patients and find higher corticosteroid use in the infected group, a difference that was not statistically significant. The paper therefore does not establish immunosuppressive medications as a predisposing factor for colonization. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • Approximately 35% of patients who received corticosteroids were associated with C. auris colonization.

    “Studies assessing potential risk factors of C. auris show that ~35% of patients who received corticosteroids were associated with C. auris colonization [42,54]”

    From Host–Candida auris interactions in the skin (2026) · cites this paper as [54]

    Results §3.1 reports that 34.6% of colonized patients were receiving corticosteroids, compared with 83.3% of infected patients; the difference was not statistically significant (p = 0.064). The claim reverses the denominator: the paper does not say that approximately 35% of patients receiving corticosteroids were colonized. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. [1]Satoh K. Makimura K. Hasumi Y. Nishiyama Y. Uchida K. Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital Microbiol. Immunol. 2009 53 41 44 10.1111/j.1348-0421.2008.00083.x 19161556 · DOI · Paper page
  2. [3]Chowdhary A. Voss A. Meis J.F. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J. Hosp. Infect. 2016 94 209 212 10.1016/j.jhin.2016.08.004 27634564 · DOI · Paper page
  3. [4]Lockhart S.R. Etienne K.A. Vallabhaneni S. Farooqi J. Chowdhary A. Govender N.P. Colombo A.L. Calvo B. Cuomo C.A. Desjardins C.A. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses Clin. Infect. Dis. 2017 64 134 140 10.1093/cid/ciw691 27988485 PMC5215215 · DOI · Paper page
  4. [5]Suphavilai C. Ko K.K.K. Lim K.M. Tan M.G. Boonsimma P. Chu J.J.K. Goh S.S. Rajandran P. Lee L.C. Tan K.Y. Detection and characterisation of a sixth Candida auris clade in Singapore: A genomic and phenotypic study Lancet Microbe 2024 5 100878 10.1016/S2666-5247(24)00101-0 39008997 · DOI
  5. [7]Vallabhaneni S. Kallen A. Tsay S. Chow N. Welsh R. Kerins J. Kemble S.K. Pacilli M. Black S.R. Landon E. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013–August 2016 Am. J. Transplant. 2017 17 296 299 10.1111/ajt.14121 28029734 · DOI · Paper page
  6. [8]Bing J. Du H. Guo P. Hu T. Xiao M. Lu S. Nobile C.J. Chu H. Huang G. Candida auris-associated hospitalizations and outbreaks, China, 2018–2023 Emerg. Microbes Infect. 2024 13 2302843 10.1080/22221751.2024.2302843 38238874 PMC10802803 · DOI
  7. [9]Lee W.G. Shin J.H. Uh Y. Kang M.G. Kim S.H. Park K.H. Jang H.-C. First three reported cases of nosocomial fungemia caused by Candida auris J. Clin. Microbiol. 2011 49 3139 3142 10.1128/JCM.00319-11 21715586 PMC3165631 · DOI
  8. [10]Farooqi J.Q. Jabeen K. Saeed N. Iqbal N. Malik B. Lockhart S.R. Zafar A. Brandt M.E. Hasan R. Invasive candidiasis in Pakistan: Clinical characteristics, species distribution and antifungal susceptibility J. Med. Microbiol. 2013 62 259 268 10.1099/jmm.0.048785-0 23105021 PMC4629241 · DOI
  9. [11]Pfaller M.A. Diekema D.J. Turnidge J.D. Castanheira M. Jones R.N. Twenty years of the SENTRY antifungal surveillance program: Results for Candida species from 1997–2016 Open Forum Infect. Dis. 2019 6 S79 S94 10.1093/ofid/ofy358 30895218 PMC6419901 · DOI · Paper page
  10. [12]Kean R. Ramage G. Combined antifungal resistance and biofilm tolerance: The global threat of Candida auris mSphere 2019 4 e00458-19 10.1128/mSphere.00458-19 31366705 PMC6669339 · DOI
  11. [13]Welsh R.M. Bentz M.L. Shams A. Houston H. Lyons A. Rose L.J. Litvintseva A.P. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface J. Clin. Microbiol. 2017 55 2996 3005 10.1128/JCM.00921-17 28747370 PMC5625385 · DOI · Paper page
  12. [14]Cosio T. Pica F. Fontana C. Pistoia E.S. Favaro M. Valsecchi I. Zarabian N. Campione E. Botterel F. Gaziano R. Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans J. Fungi 2024 10 294 10.3390/jof10040294 PMC11050938 38667965 · DOI
  13. [15]Magrì C. De Carolis E. Ivagnes V. Di Pilato V. Spruijtenburg B. Marchese A. Meijer E.F.J. Chowdhary A. Sanguinetti M. “CLADE-FINDER”: Candida auris Lineage Analysis Determination by Fourier Transform Infrared Spectroscopy and Artificial Neural Networks Microorganisms 2024 12 2153 10.3390/microorganisms12112153 39597542 PMC11596196 · DOI
  14. [16]Zhu Y. O’Brien B. Leach L. Clarke A. Bates M. Adams E. Ostrowsky B. Quinn M. Dufort E. Southwick K. Laboratory analysis of an outbreak of Candida auris in New York from 2016 to 2018: Impact and lessons learned J. Clin. Microbiol. 2020 58 e01503 e01519 10.1128/JCM.01503-19 31852764 PMC7098748 · DOI
  15. [17]Eyre D.W. Sheppard A.E. Madder H. Moir I. Moroney R. Quan T.P. Griffiths D. George S. Butcher L. Morgan M. A Candida auris outbreak and its control in an Intensive Care Setting N. Engl. J. Med. 2018 379 1322 1331 10.1056/NEJMoa1714373 30281988 · DOI · Paper page
  16. [18]Edwards J.E. Jr. Dolin R. Blaser M.J. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases 8th ed. Elsevier Philadelphia, PA, USA 2015 2879 2894
  17. [19]Kathuria S. Singh P.K. Sharma C. Prakash A. Masih A. Kumar A. Meis J.F. Chowdhary A. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method J. Clin. Microbiol. 2015 53 1823 1830 10.1128/JCM.00367-15 25809970 PMC4432077 · DOI
  18. [20]Borman A.M. Szekely A. Johnson E.M. Comparative Pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species mSphere 2016 1 e00189-16 10.1128/mSphere.00189-16 27547827 PMC4990711 · DOI · Paper page
  19. [21]Kim T.-H. Kweon O.J. Kim H.R. Lee M.-K. Identification of uncommon Candida species using commercial identification systems J. Microbiol. Biotechnol. 2016 26 2206 2213 10.4014/jmb.1609.09012 27713213 · DOI
  20. [22]Kordalewska M. Zhao Y. Lockhart S.R. Chowdhary A. Berrio I. Perlin D.S. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris J. Clin. Microbiol. 2017 55 2445 2452 10.1128/JCM.00630-17 28539346 PMC5527423 · DOI
  21. [23]Leach L. Zhu Y. Chaturvedi S. Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples J. Clin. Microbiol. 2018 56 e01223-17 10.1128/JCM.01223-17 29187562 PMC5786737 · DOI
  22. [24]Sexton D.J. Kordalewska M. Bentz M.L. Welsh R.M. Perlin D.S. Litvintseva A.P. Direct detection of emergent fungal pathogen Candida auris in clinical skin swabs by SYBR Green-Based Quantitative PCR Assay J. Clin. Microbiol. 2018 56 e01337-18 10.1128/JCM.01337-18 30232130 PMC6258843 · DOI
  23. [25]Sexton D.J. Bentz M.L. Welsh R.M. Litvintseva A.P. Evaluation of a new T2 Magnetic Resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples Mycoses 2018 61 786 790 10.1111/myc.12817 29938838 · DOI
  24. [28]Stathi A. Loukou I. Kirikou H. Petrocheilou A. Moustaki M. Velegraki A. Zachariadou L. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019 Eurosurveillance 2019 24 1900400 10.2807/1560-7917.ES.2019.24.29.1900400 31339093 PMC6652113 · DOI
  25. [29]Singer M. Deutschman C.S. Seymour C.W. Shankar-Hari M. Annane D. Bauer M. Bellomo R. Bernard G.R. Chiche J.-D. Coopersmith C.M. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 2016 315 801 810 10.1001/jama.2016.0287 26903338 PMC4968574 · DOI · Paper page
  26. [32]Katsiari M. Mavroidi A. Kesesidis N. Palla E. Zourla K. Ntorlis K. Konstantinidis K. Laskou M. Strigklis K. Sakkalis A. Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit J. Fungi 2023 9 243 10.3390/jof9020243 PMC9964037 36836357 · DOI
  27. [33]Long B. Lacy A.J. Koyfman A. Liang S.Y. Candida auris: A focused review for emergency clinicians Am. J. Emerg. Med. 2024 84 162 167 10.1016/j.ajem.2024.07.062 39137491 · DOI
  28. [34]Dennis E.K. Chaturvedi S. Chaturvedi V. So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories Front. Microbiol. 2021 12 757835 10.3389/fmicb.2021.757835 34691009 PMC8529189 · DOI
  29. [35]Chowdhary A. Tarai B. Singh A. Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020 Emerg. Infect. Dis. 2020 26 2694 2696 10.3201/eid2611.203504 32852265 PMC7588547 · DOI
  30. [36]Villanueva-Lozano H. Treviño-Rangel R.d.J. González G.M. Ramírez-Elizondo M.T. Lara-Medrano R. Aleman-Bocanegra M.C. Guajardo-Lara C.E. Gaona-Chávez N. Castilleja-Leal F. Torre-Amione G. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico Clin. Microbiol. Infect. 2021 27 813 816 10.1016/j.cmi.2020.12.030 33429028 PMC7835657 · DOI
  31. [38]Rodriguez J.Y. Le Pape P. Lopez O. Esquea K. Labiosa A.L. Alvarez-Moreno C. Candida auris: A latent threat to critically ill patients with coronavirus disease 2019 Clin. Infect. Dis. 2021 73 e2836 e2837 10.1093/cid/ciaa1595 33070175 PMC7665436 · DOI
  32. [40]Kean R. McKloud E. Townsend E.M. Sherry L. Delaney C. Jones B.L. Williams C. Ramage G. The comparative efficacy of antiseptics against Candida auris biofilms Int. J. Antimicrob. Agents 2018 52 673 677 10.1016/j.ijantimicag.2018.05.007 29775686 · DOI
  33. [41]Schelenz S. Hagen F. Rhodes J.L. Abdolrasouli A. Chowdhary A. Hall A. Ryan L. Shackleton J. Trimlett R. Meis J.F. First hospital outbreak of the globally emerging Candida auris in a European hospital Antimicrob. Resist. Infect. Control 2016 5 35 10.1186/s13756-016-0132-5 27777756 PMC5069812 · DOI · Paper page
  34. [42]Yadav A. Singh A. Wang Y. Hi van Haren M. Singh A. de Groot T. Meis J.F. Xu J. Chowdhary A. Colonisation and transmission dynamics of Candida auris among chronic respiratory diseases patients hospitalised in a Chest Hospital, Delhi, India: A comparative analysis of whole genome sequencing and microsatellite typing J. Fungi 2021 7 81 10.3390/jof7020081 PMC7910912 33530297 · DOI
  35. [44]Forsberg K. Woodworth K. Walters M. Berkow E.L. Jackson B. Chiller T. Vallabhaneni S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen Med. Mycol. 2019 57 1 12 10.1093/mmy/myy054 30085270 · DOI · Paper page
  36. [45]Biran R. Cohen R. Finn T. Brosh-Nissimov T. Rahav G. Yahav D. Amit S. Shachor-Meyouhas Y. Atamna A. Bishara J. Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021–2022 Emerg. Infect. Dis. 2023 29 1297 1301 10.3201/eid2907.221888 37347492 PMC10310389 · DOI
  37. [46]Shastri P.S. Shankarnarayan S.A. Oberoi J. Rudramurthy S.M. Wattal C. Chakrabarti A. Candida auris candidaemia in an intensive care unit-prospective observational study to evaluate epidemiology, risk factors, and outcome J. Crit. Care 2020 57 42 48 10.1016/j.jcrc.2020.01.004 32062286 · DOI · Paper page
  38. [47]Kenters N. Kiernan M. Chowdhary A. Denning D.W. Pemán J. Saris K. Schelenz S. Tartari E. Widmer A. Meis J.F. Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting Int. J. Antimicrob. Agents 2019 54 400 406 10.1016/j.ijantimicag.2019.08.013 31419480 · DOI · Paper page
  39. [48]Garcia-Bustos V. Salavert M. Ruiz-Gaitán A.C. Cabanero-Navalon M.D. Sigona-Giangreco I.A. Pemán J. A clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patients Clin. Microbiol. Infect. 2020 26 1507 1513 10.1016/j.cmi.2020.02.001 32061792 · DOI
  40. [49]Briano F. Magnasco L. Sepulcri C. Dettori S. Dentone C. Mikulska M. Ball L. Vena A. Robba C. Patroniti N. Candida auris candidemia in critically ill, colonized patients: Cumulative incidence and risk factors Infect. Dis. Ther. 2022 11 1149 1160 10.1007/s40121-022-00625-9 35404010 PMC8995918 · DOI
  41. [50]Sayeed M.A. Farooqi J. Jabeen K. Awan S. Mahmood S.F. Clinical spectrum and factors impacting outcome of Candida auris: A single center study from Pakistan BMC Infect. Dis. 2019 19 384 10.1186/s12879-019-3999-y 31060514 PMC6501321 · DOI
  42. [51]Cortegiani A. Misseri G. Fasciana T. Giammanco A. Giarratano A. Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris J. Intensive Care 2018 6 69 10.1186/s40560-018-0342-4 30397481 PMC6206635 · DOI
  43. [52]Burrack L.S. Todd R.T. Soisangwan N. Wiederhold N.P. Selmecki A. Genomic diversity across Candida auris clinical isolates shapes rapid development of antifungal resistance in vitro and in vivo mBio 2022 13 e00842-22 10.1128/mbio.00842-22 35862787 PMC9426540 · DOI · Paper page
  44. [53]Mulet-Bayona J.V. Salvador-Garcia C. Tormo-Palop N. Gimeno-Cardona C. Recurrent candidemia and isolation of echinocandin-resistant Candida auris in a patient with a long-term central catheter Enferm. Infecc. Microbiol. Clin. (Engl. Ed.) 2022 40 334 335 10.1016/j.eimce.2022.03.011 35550364 · DOI
  45. [54]Biagi M.J. Wiederhold N.P. Gibas C. Wickes B.L. Lozano V. Bleasdale S.C. Danziger L. Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria Open Forum Infect. Dis. 2019 6 ofz262 10.1093/ofid/ofz262 31281859 PMC6602379 · DOI
  46. [55]Proctor D.M. Drummond R.A. Lionakis M.S. Segre J.A. One population, multiple lifestyles: Commensalism and pathogenesis in the human mycobiome Cell Host Microbe 2023 31 539 553 10.1016/j.chom.2023.02.010 37054674 PMC10155287 · DOI · Paper page
  47. [56]Caballero U. Kim S. Eraso E. Quindós G. Vozmediano V. Schmidt S. Jauregizar N. In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris Antibiotics 2021 10 355 10.3390/antibiotics10040355 33800601 PMC8066733 · DOI
  48. [57]Jaggavarapu S. Burd E.M. Weiss D.S. Micafungin and amphotericin b synergy against Candida auris Lancet Microbe 2020 1 e314 e315 10.1016/S2666-5247(20)30194-4 35544183 · DOI
  49. [58]Ahmad S. Asadzadeh M. Strategies to prevent transmission of Candida auris in healthcare settings Curr. Fungal Infect. Rep. 2023 17 36 48 10.1007/s12281-023-00451-7 36718372 PMC9878498 · DOI
  50. [60]Taori S.K. Khonyongwa K. Hayden I. Athukorala G.D.A. Letters A. Fife A. Desai N. Borman A.M. Candida auris outbreak: Mortality, interventions and cost of sustaining control J. Infect. 2019 79 601 611 10.1016/j.jinf.2019.09.007 31557493 · DOI
  51. [62]Tsay S. Kallen A. Jackson B.R. Chiller T.M. Vallabhaneni S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast Clin. Infect. Dis. 2018 66 306 311 10.1093/cid/cix744 29020224 PMC5798232 · DOI
  52. [63]Sabino R. Veríssimo C. Pereira Á.A. Antunes F. Candida auris, an agent of hospital-associated outbreaks: Which challenging issues do we need to have in mind? Microorganisms 2020 8 181 10.3390/microorganisms8020181 32012865 PMC7074697 · DOI · Paper page

Cited by

Sorted by citations

Authors
Katsiari, M., Nikolaou, C., Palla, E., Theodoridou, K., Tsakris, A., & Vrioni, G.
Affiliations
  • Intensive Care Unit, Konstantopouleio-Patision General Hospital, 3-5 Theodorou Konstantopoulou Street, N. Ionia, 14233 Athens, Greece
  • Department of Microbiology, Konstantopouleio- Patision General Hospital, 3-5 Theodorou Konstantopoulou Street, N. Ionia, 14233 Athens, Greece
  • National and Kapodistrian University of Athens (GR)
Corresponding author
  • Katsiari, Maria
  • Vrioni, Georgia
ORCID
Venue
Pathogens
Publisher
MDPI AG
Published
2025-03-28
Volume
14
Issue
4
Pages
328
ISSN
2076-0817 (ISSN-L)
DOI
10.3390/pathogens14040328
PMC
PMC12030536
OpenAlex
W4408932381
Cited by
13
References
7
Citations by year
2026: 10 · 2025: 3
FWCI
10.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Pathogens (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
Candida auris, critically ill patients, intensive care unit, candidemia, colonization, multidrug resistance, fluconazole resistance, echinocandin susceptibility, amphotericin B, corticosteroids, renal replacement therapy, intensive care unit infections, mortality, infection control, MALDI-TOF identification
MeSH terms
Candida auris, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Greece, Humans, Intensive Care Units, Male, Microbial Sensitivity Tests, Middle Aged, Risk Factors, Critical Illness, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review